LNP-FORMULATED MRNA THERAPEUTICS AND USE THEREOF FOR TREATING HUMAN SUBJECTS

1 . A method of producing a therapeutic level of an antibody in a human subject in vivo, the method comprising systemically administering to the subject an LNP-formulated mRNA, the mRNA encoding the antibody, in a dose effective to produce a Cmax of at least 1 μg/mL of the antibody in serum of the subject.

2 . The method of claim 1 , wherein the Cmax is at least 2 μg/mL, at least 6 μg/mL, or at least 10 μg/mL.

3 . The method of claim 1 or 2 , wherein the antibody has a half-life of at least 50-100 days.

4 . The method of any one of claims 1 - 3 , further comprising systemically administering a second dose of the LNP-formulated mRNA within about 1 week, about 2 weeks, about 3 weeks, or about 4 weeks following the first dose.

5 . The method of any one of claims 1 - 4 , wherein the Cmax following the second dose is equal to or greater than the Cmax following the first dose.

6 . The method of claim 5 , wherein the Cmax following the second dose is at least 1.1-fold, 1.4-fold, or 1.8-fold greater than the Cmax following the first dose.

7 . The method of any one of claims 1 - 6 , wherein the dose is between 0.1-0.6 mg/kg.

8 . The method of claim 7 , wherein the dose is 0.1, 0.3, 0.45, or 0.6 mg/kg.

9 . The method of any one of claims 1 - 8 , wherein the therapeutic level of the antibody in serum is maintained for a duration following systemic administration.

10 . The method of claim 9 , wherein the duration is at least 12 weeks, at least 13 weeks, at least 14 weeks, at least 15 weeks, at least 16 weeks, at least 18 weeks, at least 19 weeks, at least 20 weeks, at least 21 weeks, at least 22 weeks, at least 23 weeks, or at least 24 weeks.

11 . The method of any one of claims 1 - 10 , wherein the antibody comprises an antibody heavy chain (HC) and an antibody light chain (LC), and wherein the HC and LC are encoded on separate mRNAs.

12 . The method of claim 11 , wherein the mRNAs encoding the HC and LC are co-formulated in the same LNP, optionally at a 2:1 (HC:LC) w/w ratio.

13 . The method of claim 11 or 12 , wherein when the LNP-formulated mRNA is systemically administered, the HC and LC are expressed from separate mRNAs and combined to form the antibody.

14 . The method of any one of claims 1 - 10 , wherein the antibody comprises an engineered single chain antibody, and wherein the HC and LC are encoded by a single mRNA.

15 . A method of producing a therapeutic level of an antibody in a human subject in vivo, the method comprising systemically administering to the subject an LNP-formulated mRNA, the mRNA encoding the antibody, in a first dose effective to produce a Cmax of at least 1 μg/mL of the antibody in serum of the subject, and at least one second dose effective to produce a Cmax equal to or greater than a Cmax following the first dose.

16 . The method of claim 15 , wherein the Cmax following the second dose is at least 1.1-fold, 1.4-fold, or 1.8-fold greater than the Cmax following the first dose.

17 . The method of claim 15 or 16 , wherein the Cmax following the first dose is at least 2 μg/mL, at least 6 μg/mL, or at least 10 μg/mL.

18 . The method of any one of claims 15 - 17 , wherein the first and second dose of LNP-formulated mRNA is between 0.1-0.6 mg/kg.

19 . The method of any one of claims 15 - 18 , wherein the second dose is administered once weekly, once every 2 weeks, once every 3 weeks, or once every 4 weeks.

20 . The method of any one of claims 15 - 19 , wherein the therapeutic level of the antibody in serum is maintained for a duration following systemic administration.

21 . The method of claim 20 , wherein the duration is at least 12 weeks, at least 13 weeks, at least 14 weeks, at least 15 weeks, at least 16 weeks, at least 18 weeks, at least 19 weeks, at least 20 weeks, at least 21 weeks, at least 22 weeks, at least 23 weeks, or at least 24 weeks.

22 . The method of any one of the preceding claims, wherein the antibody is a prophylactic antibody, optionally for use in protecting the subject against an infectious disease, optionally wherein the subject is naive for or uninfected by the infectious disease.

23 . The method of claim 22 , wherein the therapeutic level of the prophylactic antibody in serum is sufficient to neutralize a target infectious agent.

24 . The method of any one of the preceding claims, wherein the LNP comprises an ionizable amino lipid, a phospholipid, a cholesterol lipid or cholesterol-derivative lipid, a PEG-lipid or conjugated lipid.

25 . The method of claim 24 , wherein the ionizable amino lipid is Compound 1.

26 . The method of claim 24 or 25 , wherein the PEG-lipid is Compound 2.

27 . The method of any one of claims 24 - 26 , wherein the LNP comprises 20-60 mol % ionizable amino lipid and 0.5-15 mol % PEG lipid.

28 . The method of any one of claims 24 - 27 , wherein the LNP comprises 20-60 mol % ionizable amino lipid, 5-25% DSPC, 25-55% cholesterol, and 0.5-15 mol % PEG lipid.

29 . The method of any one of the preceding claims, wherein the LNP-formulated mRNA is systemically administered via intravenous infusion or intravenous injection.

30 . The method of any one of claims 1 - 29 , wherein the LNP and mRNA are formulated in the same vial.

31 . The method of any one of claims 1 - 29 , wherein the LNP and mRNA are formulated in separate vials.

32 . The method of claim 31 , wherein the LNP and mRNA are combined prior to being systemically administered.

33 . The method of any one of claims 1 - 32 , wherein the LNP-formulated mRNA is systemically administered via intravenous infusion for a duration of 30 minutes to 4 hours.